Kriya | search
Click here to view Kriya news from 60+ newspapers.
Bookmark or Share- Our Team: Leaders in Gene Therapy - Kriya TherapeuticsShankar Ramaswamy is the Co-Founder, Chairman, and Chief Executive Officer of Kriya Therapeutics. Dr. Ramaswamy was part of the early foundational team at Roivant Sciences, where he was responsible for helping to identify and evaluate assets across therapeutic areas and launch its first public subsidiary company.
- Gene Therapy Company Redefined | Kriya TherapeuticsKriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits.
- Opthalmology: Gene Therapy for Geographic Atrophy - Kriya TherapeuticsKriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with the objective of slowing Geographic Atrophy lesion growth and vision loss.
- Careers: Future of Gene Therapy - Kriya TherapeuticsKriya is Changing the Future of Gene Therapy. We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day.
- Pipeline - Kriya TherapeuticsKriya is developing a portfolio of one-time gene therapies to address common diseases. Our current pipeline includes three main therapeutic areas: Kriya’s pipeline candidates are investigational and have not been approved as safe or effective by any regulatory health authority.
More
